Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?

A target A1C of <7% is the recommended goal for most people with type 2 diabetes. However, many are not achieving this target with their current treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are highly efficacious in achieving glycemic control and could aid primary care providers (...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Aaron, Miller, Eden M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115618/
https://www.ncbi.nlm.nih.gov/pubmed/37092151
http://dx.doi.org/10.2337/cd22-0027
_version_ 1785028247956750336
author King, Aaron
Miller, Eden M.
author_facet King, Aaron
Miller, Eden M.
author_sort King, Aaron
collection PubMed
description A target A1C of <7% is the recommended goal for most people with type 2 diabetes. However, many are not achieving this target with their current treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are highly efficacious in achieving glycemic control and could aid primary care providers (PCPs) in getting patients to their A1C target. However, despite their potential, use of GLP-1 receptor agonists in the primary care setting is limited. This review provides guidance for PCPs on how to help patients achieve their glycemic target and overcome perceived barriers of GLP-1 receptor agonist use, with the overall goal of improving PCP confidence in prescribing these agents.
format Online
Article
Text
id pubmed-10115618
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-101156182023-06-15 Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low? King, Aaron Miller, Eden M. Clin Diabetes Feature Articles A target A1C of <7% is the recommended goal for most people with type 2 diabetes. However, many are not achieving this target with their current treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are highly efficacious in achieving glycemic control and could aid primary care providers (PCPs) in getting patients to their A1C target. However, despite their potential, use of GLP-1 receptor agonists in the primary care setting is limited. This review provides guidance for PCPs on how to help patients achieve their glycemic target and overcome perceived barriers of GLP-1 receptor agonist use, with the overall goal of improving PCP confidence in prescribing these agents. American Diabetes Association 2023 2022-11-03 /pmc/articles/PMC10115618/ /pubmed/37092151 http://dx.doi.org/10.2337/cd22-0027 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Feature Articles
King, Aaron
Miller, Eden M.
Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
title Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
title_full Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
title_fullStr Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
title_full_unstemmed Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
title_short Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
title_sort glucagon-like peptide 1 receptor agonists have the potential to revolutionize the attainment of target a1c levels in type 2 diabetes—so why is their uptake so low?
topic Feature Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115618/
https://www.ncbi.nlm.nih.gov/pubmed/37092151
http://dx.doi.org/10.2337/cd22-0027
work_keys_str_mv AT kingaaron glucagonlikepeptide1receptoragonistshavethepotentialtorevolutionizetheattainmentoftargeta1clevelsintype2diabetessowhyistheiruptakesolow
AT milleredenm glucagonlikepeptide1receptoragonistshavethepotentialtorevolutionizetheattainmentoftargeta1clevelsintype2diabetessowhyistheiruptakesolow

Ejemplares similares